I don't expect the Lovenox hearing on Aug 17 to move the share price much, if at all. The Markman ruling on Copaxone, which could come at any time, is another story, however; if positive for MNTA, it could move the share price to a material degree.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”